Somaiya Mayur Ian (CIK 1760303) reported 15 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-01-22). Recent activity: Buy NAMS (60,216 shares), Sell NAMS (900 shares), Sell NAMS (39,712 shares), Sell NAMS (19,604 shares), Buy NAMS (39,784 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-22 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Buy | 60,216 | $557,600 |
| 2026-01-22 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 900 | $27,576 |
| 2026-01-22 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 39,712 | $1.3M |
| 2026-01-22 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 19,604 | $634,778 |
| 2026-01-22 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Buy | 39,784 | $368,400 |
| 2026-01-22 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 15,422 | $512,782 |
| 2026-01-22 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 24,362 | $823,436 |
| 2026-01-07 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 5,118 | $170,174 |
| 2026-01-07 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Buy | 25,500 | $0 |
| 2025-01-29 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Buy | 46,983 | $435,063 |
| 2025-01-29 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 33,679 | $0 |
| 2025-01-29 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 13,304 | $0 |
| 2025-01-29 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Buy | 14,900 | $137,974 |
| 2025-01-29 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 11,495 | $0 |
| 2025-01-29 | NewAmsterdam Pharma Co N.V. (NAMS) | Chief Financial Officer | Sell | 3,405 | $0 |
Source: SEC Form 4 filings · as of 2026-01-22